Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency

Affiliations

• ¹ Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland.
• ² Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
• ³ Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
• ⁴ University Center for Immunology, University Hospital Basel, Basel, Switzerland.
• ⁵ Swiss Society for Inborn Errors of Immunity, Zurich, Switzerland.
• ⁶ ADR-AC GmbH, Adverse Drug Reactions-Analysis and Consulting, Bern, Switzerland; Löwenpraxis Luzern und Klinik St Anna, Lucerne, Switzerland.
• ⁷ Department of Rheumatology and Clinical Immunology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Center for Chronic Immunodeficiency, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
• ⁸ University Center for Immunology, University Hospital Basel, Basel, Switzerland; Immunodeficiency Lab, Department Biomedicine, University of Basel, Basel, Switzerland.
• ⁹ Translational Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland; University Center for Immunology, University Hospital Basel, Basel, Switzerland. Electronic address: christoph.berger@usb.ch.